menu search

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial […] The post Bellerophon Provides Clinical Program Update and Reports First Quarte... Read More
Posted: May 15 2023, 20:50
Author Name: forextv
Views: 081735

Search within

Pages Search Results: